Reckitt Benckiser Group PLC (OTCMKTS:RBGLY – Get Free Report)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $14.76 and traded as low as $12.53. Reckitt Benckiser Group shares last traded at $12.67, with a volume of 566,951 shares trading hands.
Analyst Upgrades and Downgrades
RBGLY has been the subject of a number of research analyst reports. Zacks Research upgraded shares of Reckitt Benckiser Group from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Morgan Stanley upgraded shares of Reckitt Benckiser Group from an “equal weight” rating to an “overweight” rating in a research report on Monday, March 16th. Finally, Kepler Capital Markets upgraded shares of Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Reckitt Benckiser Group presently has an average rating of “Moderate Buy”.
View Our Latest Stock Analysis on RBGLY
Reckitt Benckiser Group Stock Up 2.1%
About Reckitt Benckiser Group
Reckitt Benckiser Group plc is a multinational consumer goods company that develops, manufactures and markets health, hygiene and home products. Its portfolio spans over-the-counter medicines and health products, personal and sexual wellness, surface and laundry cleaning, and household care. The company owns a number of well-known global brands across these categories, including Lysol and Dettol in disinfectants and hygiene, Durex in sexual wellness, Nurofen in analgesics, and Finish in dishwashing products.
The firm has its corporate headquarters in the United Kingdom and sells products in markets around the world, serving consumers across North America, Europe, Asia, Latin America, the Middle East and Africa.
Featured Articles
- Five stocks we like better than Reckitt Benckiser Group
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.
